AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3319536 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g/day GVG
Number of subjects: 75
Study 3319536 — intervention group
Group type: COMPARATOR
Intervention: 1.5 g/day GVG
Number of subjects: 75
Study 31129775 — intervention group
Group type: EXPERIMENTAL
Intervention: Erigo® verticalization
Number of subjects: 44
Study 31129775 — intervention group
Group type: COMPARATOR
Intervention: Conventional neurorehabilitation
Number of subjects: 44
Study 28705663 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic beer (BAC of 0.03)
Number of subjects: 0
Study 28705663 — intervention group
Group type: COMPARATOR
Intervention: Non-alcoholic beer (placebo)
Number of subjects: 0
Study 26101276 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole prophylaxis
Number of subjects: 200
Study 26101276 — intervention group
Group type: COMPARATOR
Intervention: Mefloquine
Number of subjects: 200
Study 26101276 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy
Number of subjects: 200
Study 23432812 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD‐CV co‐administered with DTPa‐HBV‐IPV/Hib
Number of subjects: 300
Study 23432812 — intervention group
Group type: COMPARATOR
Intervention: Control group (DTPa‐HBV‐IPV/Hib alone)
Number of subjects: 300
Study 20855188 — intervention group
Group type: EXPERIMENTAL
Intervention: NIOX MINO(®) analyser
Number of subjects: 17
Study 19521297 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-gauge Quincke spinal needle (Group Q)
Number of subjects: 45
Study 19521297 — intervention group
Group type: COMPARATOR
Intervention: 25-gauge ballpen spinal needle (Group B)
Number of subjects: 45
Study 19521297 — intervention group
Group type: COMPARATOR
Intervention: 25-gauge pencil-point spinal needle (Group P)
Number of subjects: 45
Study 17534460 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary sodium intake of less than 100 mmol/day for prevention of hypertension; limited to 65 mmol/day to 100 mmol/day for hypertensive patients.
Number of subjects: 0
Study 17534460 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise for 30 to 60 minutes, four to seven days per week.
Number of subjects: 0
Study 17534460 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure targets: lower than 140/90 mmHg for all patients; lower than 130/80 mmHg for those with diabetes or chronic kidney disease.
Number of subjects: 0
Study 17534460 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide diuretics as initial therapy for adults without compelling indications for other agents.
Number of subjects: 0
Study 17534460 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors, long-acting CCBs, ARBs, or beta-blockers as first-line therapy for diastolic and/or systolic hypertension.
Number of subjects: 0
Study 17534460 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors recommended for nondiabetic chronic kidney disease patients.
Number of subjects: 0
Study 17534460 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy for selected high-risk patients with hypertension.
Number of subjects: 0
Study 15166932 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa)
Number of subjects: 0
Study 15166932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11588128 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (30 mg daily)
Number of subjects: 103
Study 11588128 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 10051942 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam-sufentanil (Group I)
Number of subjects: 32
Study 10051942 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil-enflurane (Group II)
Number of subjects: 32
Study 7987837 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CP) at 1000 mg/m2 infused over 20 min
Number of subjects: 6
Study 7987837 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (CP) at 1000 mg/m2 infused over 20 min with SR-2508 at 5 g/m2 infused over 20 min
Number of subjects: 6
Study 2557307 — intervention group
Group type: EXPERIMENTAL
Intervention: Single daily fractions to the liver (3.0 Gy external beam radiation, total dose 21.0 Gy) with chemotherapy (Adriamycin 15 mg IV and 5-FU 500 mg IV, 2 hr before treatment on days 1, 3, 5, and 7)
Number of subjects: 135
Study 2557307 — intervention group
Group type: COMPARATOR
Intervention: Hyperfractionated whole liver external beam irradiation (1.2 Gy twice daily, 4 hr between treatments, 5 days per week to 24.0 Gy, 10 MV photons) with the same chemotherapy regimen
Number of subjects: 135
Study 1149303 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine hydrochloride (0.75 mg s.c.)
Number of subjects: 9
Study 1149303 — intervention group
Group type: COMPARATOR
Intervention: L-DOPA (500 mg p.o.)
Number of subjects: 9
Study 1149303 — intervention group
Group type: COMPARATOR
Intervention: Benztropine mesylate (1 mg i.m.)
Number of subjects: 9
Study 31786655 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 15480
Study 31786655 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation with n-3 fatty acids
Number of subjects: 15480
Study 31273298 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurochemical biomarkers in spinal cord injury (SCI)
Number of subjects: 0
Study 28618299 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet guided self‐help cognitive‐behavioural treatment (ICBT)
Number of subjects: 120
Study 28618299 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 120
Study 26441220 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous micropump infusion of atropine and pralidoxime chloride
Number of subjects: 60
Study 26441220 — intervention group
Group type: COMPARATOR
Intervention: Repeated-bolus doses of atropine and pralidoxime chloride
Number of subjects: 60
Study 23334108 — intervention group
Group type: EXPERIMENTAL
Intervention: Losses in various settings (Study 1-3)
Number of subjects: 0
Study 23334108 — intervention group
Group type: EXPERIMENTAL
Intervention: Losses with no contrast effects (Study 4-5)
Number of subjects: 0
Study 21676930 — intervention group
Group type: EXPERIMENTAL
Intervention: Crowded object recognition
Number of subjects: 0
Study 21676930 — intervention group
Group type: EXPERIMENTAL
Intervention: Crowding effect on object recognition
Number of subjects: 0
Study 20209468 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyruvate supplementation (2 g per day for 4 weeks)
Number of subjects: 22
Study 20209468 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyruvate supplementation
Number of subjects: 22
Study 20209468 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 22
Study 17035735 — intervention group
Group type: EXPERIMENTAL
Intervention: HEXAVAC
Number of subjects: 7151
Study 17035735 — intervention group
Group type: COMPARATOR
Intervention: PENTACOQ and HBVAXPRO
Number of subjects: 7151
Study 15023205 — intervention group
Group type: EXPERIMENTAL
Intervention: Errata considered worthwhile obtaining (from information specialist's perspective)
Number of subjects: 100
Study 15023205 — intervention group
Group type: EXPERIMENTAL
Intervention: Errata classified as likely to affect meta-analysis (from experienced reviewer/public health consultant's perspective)
Number of subjects: 100
Study 15023205 — intervention group
Group type: EXPERIMENTAL
Intervention: Errata with significant errors affecting interpretation of RCT (from experienced reviewer/public health consultant's perspective)
Number of subjects: 100
Study 15023205 — intervention group
Group type: EXPERIMENTAL
Intervention: Errata not considered important (from experienced reviewer/public health consultant's perspective)
Number of subjects: 100
Study 15023205 — intervention group
Group type: EXPERIMENTAL
Intervention: Errata that matter in changing conclusions of systematic review
Number of subjects: 100
Study 15023205 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall assessment of errata
Number of subjects: 100
Study 10694117 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D (2 h at 56% VO2max followed by eccentric contractions)
Number of subjects: 24
Study 10694117 — intervention group
Group type: EXPERIMENTAL
Intervention: Group F (2 h at 56% VO2max with carbohydrate-electrolyte beverage followed by eccentric contractions)
Number of subjects: 24
Study 10694117 — intervention group
Group type: COMPARATOR
Intervention: Group C (10 sets of 10 eccentric contractions)
Number of subjects: 24
Study 10694117 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 24
Study 10694117 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D
Number of subjects: 24
Study 9234801 — intervention group
Group type: EXPERIMENTAL
Intervention: Strain chi4073 (delta cya delta crp delta cdt S. typhi Ty2) - 5 x 10(5) to 5 x 10(8) CFU
Number of subjects: 40
Study 9234801 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmid-containing derivatives of chi4073
Number of subjects: 40
Study 9234801 — intervention group
Group type: EXPERIMENTAL
Intervention: Strain chi4073
Number of subjects: 40
Study 9234801 — intervention group
Group type: EXPERIMENTAL
Intervention: Chi4073 derivatives with Asd+ vector (with and without HBc-pre-S fusion)
Number of subjects: 40
Study 8379835 — intervention group
Group type: EXPERIMENTAL
Intervention: 20pps electrical stimulation
Number of subjects: 30
Study 8379835 — intervention group
Group type: EXPERIMENTAL
Intervention: 45pps electrical stimulation
Number of subjects: 30
Study 8379835 — intervention group
Group type: EXPERIMENTAL
Intervention: 80pps electrical stimulation
Number of subjects: 30
Study 8379835 — intervention group
Group type: COMPARATOR
Intervention: Control (left limb)
Number of subjects: 30
Study 3934915 — intervention group
Group type: EXPERIMENTAL
Intervention: s.c. salbutamol 0.5 mg
Number of subjects: 14
Study 3934915 — intervention group
Group type: COMPARATOR
Intervention: Placebo 0.5 mg
Number of subjects: 14
Study 31980132 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT+
Number of subjects: 92
Study 31980132 — intervention group
Group type: COMPARATOR
Intervention: CogPack
Number of subjects: 92
Study 29500603 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib 50 mg orally after ketoconazole 400 mg once daily for 3 days
Number of subjects: 60
Study 29500603 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib 150 mg orally after rifampicin 600 mg once daily for 7 days
Number of subjects: 60
Study 29500603 — intervention group
Group type: COMPARATOR
Intervention: Nintedanib alone (control for both studies)
Number of subjects: 60
Study 27724833 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy for TTM (details on dosage and duration not available)
Number of subjects: 245
Study 24584708 — intervention group
Group type: EXPERIMENTAL
Intervention: ICG-assisted surgery
Number of subjects: 48
Study 24584708 — intervention group
Group type: EXPERIMENTAL
Intervention: BBG-assisted surgery
Number of subjects: 48
Study 24584708 — intervention group
Group type: EXPERIMENTAL
Intervention: TA-assisted surgery
Number of subjects: 48
Study 24584708 — intervention group
Group type: COMPARATOR
Intervention: All groups (ICG, BBG, TA)
Number of subjects: 48
Study 21535346 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin/Metformin FDC
Number of subjects: 1250
Study 21535346 — intervention group
Group type: COMPARATOR
Intervention: Metformin Monotherapy
Number of subjects: 1250
Study 16091272 — intervention group
Group type: EXPERIMENTAL
Intervention: Subliminal words with pleasant and unpleasant meanings
Number of subjects: 0
Study 16091272 — intervention group
Group type: EXPERIMENTAL
Intervention: Subliminal words analyzed at the subword level (bigrams and trigrams)
Number of subjects: 0
Study 16091272 — intervention group
Group type: EXPERIMENTAL
Intervention: Subliminal priming
Number of subjects: 0
Study 11786454 — intervention group
Group type: EXPERIMENTAL
Intervention: Information leaflet with standard verbal reassurance (Group A)
Number of subjects: 259
Study 11786454 — intervention group
Group type: COMPARATOR
Intervention: Standard verbal reassurance without information leaflet (Group A)
Number of subjects: 259
Study 11786454 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics prescribed (Group B)
Number of subjects: 259
Study 11786454 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics prescribed (Group A)
Number of subjects: 259
Study 11477810 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhiling Decoction (ZLD)
Number of subjects: 78
Study 11477810 — intervention group
Group type: COMPARATOR
Intervention: Naofukang
Number of subjects: 78
Study 8597968 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilioinguinal-iliohypogastric nerve block performed by anaesthetist using 0.25% plain bupivicaine (0.5 ml.kg‐1)
Number of subjects: 0
Study 8597968 — intervention group
Group type: COMPARATOR
Intervention: Ilioinguinal-iliohypogastric nerve block performed by surgeon using 0.25% plain bupivicaine (0.5 ml.kg‐1)
Number of subjects: 0
Study 8597968 — intervention group
Group type: EXPERIMENTAL
Intervention: Children under two years of age
Number of subjects: 0
Study 2527678 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple daily insulin injections (three preprandial injections of short‐acting insulin (NovoPen) plus once daily extended‐acting insulin)
Number of subjects: 16
Study 2527678 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple daily insulin injections (NovoPen)
Number of subjects: 16
Study 2527678 — intervention group
Group type: COMPARATOR
Intervention: Twice daily injections of short‐ and intermediate‐acting insulin
Number of subjects: 16
Study 334436 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 25 mg
Number of subjects: 37
Study 334436 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 50 mg
Number of subjects: 37
Study 334436 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 100 mg
Number of subjects: 37
Study 334436 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 200 mg
Number of subjects: 37
Study 334436 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone (various doses)
Number of subjects: 37
Study 334436 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone (higher doses)
Number of subjects: 37
Study 334436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 30419940 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in communication skills using six strategies
Number of subjects: 600
Study 30419940 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 600
Study 30419940 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in communication skills
Number of subjects: 600
Study 27814327 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mL of absolute alcohol (ethanol)
Number of subjects: 32
Study 27814327 — intervention group
Group type: COMPARATOR
Intervention: 1.5 mL of chlorpromazine (25 mg/mL)
Number of subjects: 32
Study 23821131 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-field intraoperative MRI guidance (iMRI)
Number of subjects: 42
Study 23821131 — intervention group
Group type: COMPARATOR
Intervention: Frameless classic analogue STx biopsy (Control)
Number of subjects: 42
Study 22703927 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 821
Study 20808258 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement collaborative for diabetes management
Number of subjects: 1861
Study 20808258 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1861
Study 18277196 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Training (ET) for 6 months
Number of subjects: 61
Study 18277196 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise training)
Number of subjects: 61
Study 16880018 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered questionnaire on hair removal practices and psychological impact
Number of subjects: 88
Study 16880018 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital Anxiety and Depression Scale
Number of subjects: 88
Study 16880018 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosenberg Self-esteem Scale
Number of subjects: 88
Study 16880018 — intervention group
Group type: EXPERIMENTAL
Intervention: WHOQOL-BREF
Number of subjects: 88
Study 12925622 — intervention group
Group type: EXPERIMENTAL
Intervention: Achilles tendon lengthening
Number of subjects: 64
Study 12925622 — intervention group
Group type: COMPARATOR
Intervention: Total-contact cast
Number of subjects: 64
Study 10768588 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 578
Study 10768588 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 578
Study 10768588 — intervention group
Group type: EXPERIMENTAL
Intervention: Fathers or other caretakers employed outside the home who spoke English
Number of subjects: 578
Study 10768588 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sociodemographic characteristics
Number of subjects: 578
Study 8855675 — intervention group
Group type: EXPERIMENTAL
Intervention: roxithromycin 300 mg once daily
Number of subjects: 32
Study 1510408 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (300 mg, orally twice daily for 7 days)
Number of subjects: 56
Study 1510408 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline (100 mg, orally twice daily for 7 days)
Number of subjects: 56
Study 6392936 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg nadolol
Number of subjects: 30
Study 6392936 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg nadolol and 5 mg bendroflumethiazide
Number of subjects: 30
Study 31655942 — intervention group
Group type: EXPERIMENTAL
Intervention: IONIS-APO(a)-LRX
Number of subjects: 0
Study 31655942 — intervention group
Group type: COMPARATOR
Intervention: Traditional Lp(a)-lowering approaches (niacin, PCSK9 inhibitors, mipomersen, lomitapide, lipoprotein apheresis)
Number of subjects: 0
Study 30594232 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone application
Number of subjects: 375
Study 30594232 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathalyzer
Number of subjects: 375
Study 30594232 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 375
Study 27175476 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate juice (PGJ) (250 g)
Number of subjects: 35
Study 27175476 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented sour sobya (FS) (170 g)
Number of subjects: 35
Study 27175476 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of PGJ (150 g) and FS (140 g)
Number of subjects: 35
Study 27175476 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplements)
Number of subjects: 35
Study 27175476 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh apricot fruits (200 g)
Number of subjects: 35
Study 25004347 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency ablation
Number of subjects: 81
Study 25004347 — intervention group
Group type: COMPARATOR
Intervention: Thermal balloon ablation
Number of subjects: 81
Study 22685234 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 mg/d; n = 25)
Number of subjects: 50
Study 22685234 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 22)
Number of subjects: 50
Study 19765357 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological (NP) test battery
Number of subjects: 174
Study 19765357 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical multiple regression analysis
Number of subjects: 174
Study 19765357 — intervention group
Group type: EXPERIMENTAL
Intervention: Ordinal logistic regression model
Number of subjects: 174
Study 17850670 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person discussion (Trial One)
Number of subjects: 114
Study 17850670 — intervention group
Group type: COMPARATOR
Intervention: No pre-test information (Trial One)
Number of subjects: 114
Study 17850670 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person discussion (Trial Two)
Number of subjects: 114
Study 17850670 — intervention group
Group type: COMPARATOR
Intervention: Tablet PC-based video (Trial Two)
Number of subjects: 114
Study 16208081 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking exercise training (WET) for 30-60 minutes, 6 days a week for 12 weeks
Number of subjects: 27
Study 16208081 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking exercise training (WET)
Number of subjects: 27
Study 16208081 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 27
Study 12370850 — intervention group
Group type: EXPERIMENTAL
Intervention: LPL N291S gene variant
Number of subjects: 195
Study 12370850 — intervention group
Group type: EXPERIMENTAL
Intervention: LPL D9N and S447X variants
Number of subjects: 195
Study 12370850 — intervention group
Group type: COMPARATOR
Intervention: LPL447X allele
Number of subjects: 195
Study 12370850 — intervention group
Group type: COMPARATOR
Intervention: IRS‐1, FABP‐2, and beta3‐AR gene variants
Number of subjects: 195
Study 10428345 — intervention group
Group type: EXPERIMENTAL
Intervention: 50-g glucose challenge test
Number of subjects: 21
Study 8784218 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (VGB)
Number of subjects: 0
Study 2099963 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide administered orally (400 mg b.i.d. for 15 days)
Number of subjects: 17
Study 2099963 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide administered intramuscularly (200 mg b.i.d. for 15 days)
Number of subjects: 17
Study 2099963 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 17
Study 317255 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibate (lipid-lowering substance) administered in a double-blind trial for an average of 5.3 years.
Number of subjects: 0
Study 317255 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (control)
Number of subjects: 0
Study 317255 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibate (lipid-lowering substance)
Number of subjects: 0
Study 28929830 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative intervention process (six weekly sessions)
Number of subjects: 18
Study 28929830 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative intervention process (experimental group)
Number of subjects: 18
Study 28929830 — intervention group
Group type: COMPARATOR
Intervention: Control group (comparison group)
Number of subjects: 18
Study 27939058 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleaner burning biomass-fuelled cookstove intervention
Number of subjects: 10750